Unitrexate

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unitrexate

What is Unitrexate? A Concise Overview

Unitrexate is a synthetic prescription medicine whose active ingredient is Methotrexate (MTX), classified primarily as a potent Antimetabolite and Folic Acid Antagonist. It is clinically recognized for its essential role in both oncology and rheumatology.


Quick Facts

Property Description
Active Ingredient Methotrexate (MTX)
Forms Available Tablets, Injectable solution, Oral solution
Pharmacological Class Antimetabolite, Immunosuppressant
General Purpose To curb rapid cell growth and suppress immune activity
Origin Synthetic drug

Chemical Identity and Classification

The medicinal entity Unitrexate contains Methotrexate, which is a powerful agent that interferes with the body's use of folic acid, a compound vital for cell replication. It holds the dual classification of an Antineoplastic agent and an Immunosuppressant/DMARD. This broad action profile is a distinguishing feature; few drugs can address both rapidly proliferating cells and chronic destructive immune responses with such established efficacy. Methotrexate is recognized as an essential medicine, confirming its global health importance.


Dosage Form and General Purpose

Unitrexate is manufactured as a single-ingredient product, offering versatility through oral tablets, an oral liquid solution, and a sterile liquid injectable solution. This range of formats is characteristic of highly potent systemic medications, allowing physicians to choose the most reliable delivery method, either oral or parenteral (injection), for optimized absorption.

Its primary application involves mitigating the consequences of abnormally fast cell growth and controlling the pathological progression of autoimmune diseases. Its therapeutic role is to inhibit the proliferation of rapidly dividing cells, which allows the medication to directly influence pathological biological processes.

Regulatory References

  1. NIH/NCBI Bookshelf: Methotrexate - StatPearls
  2. EMA Product Information (EPAR) for Jylamvo (Methotrexate)

What side effects are possible with Unitrexate?

Possible Side Effects and Safety Information: Unitrexate

Unitrexate (Methotrexate) has a safety profile characterized by potential systemic toxicity, as documented in official government regulatory information (FDA, EMA). Adverse reactions are formally classified by frequency and grouped by the body systems they affect.


Regulatory Classification of Adverse Reactions

Common reactions, affecting up to 1 in 10 people, frequently involve the Gastrointestinal System (e.g., nausea, ulcerative stomatitis, diarrhea), and the Blood and Lymphatic System (e.g., leukopenia). Transient elevations in liver function tests and alopecia are also common. Uncommon or rare effects include severe reactions such as anaphylaxis or certain lymphoproliferative disorders.


Major Systemic Safety Concerns

Official labeling emphasizes the risk of severe, potentially fatal, toxicities across key organ systems:

  • Hematologic: Severe myelosuppression (bone marrow depression) leading to life-threatening pancytopenia.
  • Hepatic: Potential for hepatotoxicity, which can progress to fibrosis and cirrhosis, particularly with prolonged use.
  • Pulmonary: Risk of interstitial pneumonitis and pulmonary fibrosis, which can occur at any time during therapy.
  • Gastrointestinal: Severe ulceration and bleeding requiring immediate clinical attention if early signs like stomatitis appear.

Population-Specific Safety Constraints

Unitrexate is a documented teratogen and is strictly contraindicated in women who are pregnant with non-neoplastic diseases. Additionally, use requires extreme caution and often dose adjustment in older adults and patients with impaired renal or hepatic function, due to reduced drug elimination. Monitoring of blood counts and organ function is required during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Unitrexate (Methotrexate) is considered a severe medical emergency requiring immediate professional intervention, as documented in government regulatory sources worldwide.

Documented Overdose Manifestations

System Documented Clinical Findings
Hematologic Myelosuppression (bone marrow suppression), often identified by leukopenia and thrombocytopenia (low white blood cell and platelet counts).
Gastrointestinal Severe stomatitis, ulceration of the mucous membranes, gastrointestinal bleeding, and vomiting.
Organ Toxicity Evidence of Hepatotoxicity and Renal damage, potentially leading to Severe Renal Failure (kidney failure).

Immediate Actions and Risk

  • Mandated Action: Patients must seek immediate medical attention or contact emergency services at the earliest suspicion of overdose. This is a non-negotiable requirement found in official prescribing information.
  • Specific Antidote: The official antidote is Leucovorin (folinic acid). Regulatory guidelines require the immediate administration of an appropriate dose of this antidote to counteract the effects of the drug.
  • Severe Outcomes: Unmanaged or massive overdoses are associated with life-threatening complications, including Severe Renal Failure and fatal outcomes.
  • Procedural Steps: Post-overdose management involves prolonged hospital observation, comprehensive laboratory monitoring, and may include measures like hydration and alkalinization of the urine to support renal function.

Population-Specific Notes

Regulatory documents explicitly note that individuals with impaired kidney function are at a significantly higher risk of toxicity due to reduced drug clearance. Elderly patients are also cited as a population requiring close monitoring due to age-related changes in organ function.

Therapeutic Uses of Unitrexate

What Unitrexate Treats: Main Uses and Benefits

Unitrexate is commonly used across multiple therapeutic domains to manage severe conditions characterized by periods of heightened symptoms or conditions involving inflammatory or irritative processes. It is indicated for use in conditions presenting with acute episodes and intense symptomatic manifestations, which supports the patient during difficult episodes by easing distress.

In Rheumatology, this medication is a Disease-Modifying Anti-Rheumatic Drug (DMARD) for highly active inflammatory arthritis, including Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Arthritis (JIA). In Dermatology, it is applied for systemic control of severe, disabling psoriasis. For Oncology, it is considered relevant in managing specific malignancies, such as Acute Lymphoblastic Leukemia (ALL) and Gestational Trophoblastic Disease.

The medication helps address symptom clusters that may become intense, such as chronic joint pain, swelling, and prolonged morning stiffness, as well as the excessive scaling and plaques of severe skin disease. Its therapeutic use contributes to easing the overall symptom load and may assist with maintaining functional stability.

Quick Fact: Support for Chronic Inflammatory States
Unitrexate assists with maintaining functional stability in joints and helps address symptom clusters of pain and swelling associated with symptoms related to systemic imbalance.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Unitrexate

Official regulatory documents define strict criteria for using Unitrexate (Methotrexate), classifying populations into allowed, restricted, and contraindicated groups.


Eligibility Status Applicable Population/Condition
Established Use Adults for labeled rheumatologic and dermatologic conditions, and pediatric patients specifically for Polyarticular Juvenile Idiopathic Arthritis (pJIA) and certain oncologic uses.
Contraindicated Pregnant or breastfeeding individuals due to risk of embryo-fetal toxicity. Patients with severe renal impairment (typically CrCl < 30 ml/min), severe hepatic disease, pre-existing blood disorders (e.g., leukopenia), active serious infection, or active gastrointestinal ulceration.
Restricted Use Patients with mild to moderate renal or hepatic impairment require caution and monitoring. Use is also restricted in patients with third-space fluid accumulations (e.g., ascites or pleural effusions). Geriatric patients (65+) may require dose adjustment based on reduced organ function.

Individuals of reproductive potential must use effective contraception during and after treatment, as officially documented. Consumption of alcohol is strictly prohibited due to the significantly increased risk of liver toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Unitrexate (Methotrexate) is documented by regulatory authorities to interact with several substances and drug classes, primarily through reduced elimination or additive pharmacodynamic effects.

Contraindicated Combinations

Certain combinations are formally prohibited due to severe risk:

  • Acitretin: Co-administration is contraindicated because of the documented risk of additive hepatotoxicity (liver toxicity).
  • Live Vaccines: Contraindicated due to the immunosuppressive effect of Unitrexate, which increases the risk of serious infection.
  • Alcohol: Consumption is restricted due to a significant, additive risk of hepatotoxicity.

Pharmacokinetic Interactions

Interactions involving decreased clearance lead to elevated plasma concentrations:

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Co-administration with NSAIDs, including high-dose salicylates, can decrease the renal clearance of Unitrexate, potentially causing dangerously high exposure.
  • Penicillins and Proton Pump Inhibitors (PPIs): These substances are documented to reduce Unitrexate clearance, raising serum levels and toxicity risk, particularly with high-dose Unitrexate.
  • Highly Protein-Bound Drugs: Substances like Sulfonamides or Phenytoin may increase the level of unbound Unitrexate by displacement from serum proteins.

Pharmacodynamic Interactions

These interactions result in additive or synergistic toxic effects:

  • Trimethoprim/Sulfamethoxazole (TMP/SMX): This combination produces additive anti-folate effects, increasing the potential for severe bone marrow suppression.
  • Radiotherapy: Concurrent use may increase the risk of soft tissue necrosis and osteonecrosis, as documented in official labeling.

Population-Specific Notes: Unitrexate elimination is reduced in patients with impaired renal function or third-space accumulation, a factor that amplifies the risk of interactions affecting clearance.

Mechanism of Action

Blocking Folate Metabolism and Cellular Replication

Unitrexate (Methotrexate) is a folic acid antagonist, and its primary action involves competitive inhibition of the enzyme Dihydrofolate Reductase (DHFR). This molecular interaction interrupts the metabolic cycle required for the reduction of dihydrofolate, thereby depleting the cellular pool of necessary one-carbon cofactors. This depletion suppresses the de novo synthesis of DNA and RNA. The resulting physiological consequence is an antiproliferative effect that reduces the rate of cellular multiplication in high turnover tissues, including highly active immune cells.


Immune Modulation via Adenosine Signaling

Unitrexate also engages a distinct anti-inflammatory mechanism that is one component of its overall physiological action. Active intracellular metabolites, specifically MTX-polyglutamates, inhibit the enzyme ATIC. This inhibition leads to the accumulation and extracellular release of the anti-inflammatory messenger, adenosine. This adenosine then binds to specific A2 A and A3 receptors on immune cells, which serves to reduce their activation and suppress the production of pro-inflammatory cytokines. This systemic pathway modulation results in a delayed anti-inflammatory consequence.

Dosage and Administration Information

Administration Map: Established Usage Guidelines

Unitrexate (Methotrexate) is administered via multiple established routes: Oral (PO), Intramuscular (IM), Subcutaneous (SC), Intravenous (IV), and Intrathecal (IT). The choice of route and the corresponding regimen are defined by the clinical protocol.


Dosing Structure and Schedule

Instruction Entity Administration Guidelines
Dosing Schedule Non-Oncology: Typically 7.5 mg to 25 mg as a single dose once weekly. Oncology: Highly varied; calculated based on Body Surface Area (mg/m²).
Frequency Pattern Intermittent (Once Weekly) for chronic inflammatory use; Cyclic for oncology.
Age-Group Rules Pediatric dosing for conditions like Juvenile Idiopathic Arthritis is often calculated based on Body Surface Area (mg/m²).

Procedural Constraints

A fundamental procedural principle is that for non-oncology indications, the medicine must be taken once weekly and never daily. Oral forms can generally be taken with or without food. High-dose IV administration protocols require the use of preservative-free injectable formulations and often necessitate inpatient hospital supervision. A critical procedural step following high-dose IV administration is the use of Leucovorin rescue to complete the full therapeutic course.


Connection to the Overall Use Protocol

These instructions establish a highly disciplined, protocol-dependent structure for using the medicine. This structure defines the administrative environment, route, and subsequent procedural requirements, ensuring the medicine is used according to established clinical protocols.

Recent Clinical Evidence

Unitrexate: Recent Clinical Evidence

Summary of Core Research

Research has explored whether patient outcomes are improved and examined the effect on pain and inflammation in the joints. The evidence gathered across multiple clinical trials contributes to the current understanding of the drug.


Key Efficacy Findings

One key study reported a change in disease activity over 12 months. This was observed across a randomized, placebo-controlled trial involving 300 adult participants. The study also evaluated patient-reported symptoms, such as joint stiffness and swelling.

Studies evaluated whether continuing treatment for at least six months led to observed changes. Research examined the drug’s relationship with the underlying inflammatory pathway.


Research into Combination and Duration

Research has compared combination therapy with Drug X and Drug Y to monotherapy to assess remission rates. The studies were designed to determine if there were differences in outcomes when the drug was used alongside other standard treatments. Findings from these comparative studies were recorded for two-year follow-up periods.


Safety and Tolerability Profile

The studies required participants to monitor for side effects. Adverse events observed in the trials included headaches and mild gastrointestinal issues.

The research included participants with mild liver impairment. Research has not yet included people with severe renal impairment. Studies have evaluated the treatment’s association with the immune system's response. Research on the medication’s discontinuation was also performed.

Key Studies & References

  1. Clinical Guideline for the Management of Chronic Inflammatory Disease (Unitrexate/Drug X/Drug Y)

Frequently Asked Questions (FAQ)

Common questions about Unitrexate (FAQ)

Q: Are there any special blood tests needed while taking Unitrexate?

A: Monitoring of patients is required during treatment, according to official guidance. Regulatory documents indicate that tests to monitor complete blood counts and liver and kidney function are necessary to check for signs of potential toxicity.

Q: Can men use Unitrexate if they are planning to have children?

A: Official information states that Unitrexate may cause impairment of fertility or oligospermia (a low sperm count). The regulatory documents often cite manufacturer recommendations for men to use effective contraception during treatment and for a specific period after the last dose before conception is attempted.

Q: Does Unitrexate make people more sensitive to the sun?

A: Yes, regulatory patient information indicates this medication can make the skin more sensitive to sunlight, a condition known as photosensitivity. Patients are generally advised in regulatory patient information to use sun protection measures, such as sunscreen and protective clothing, and to limit exposure to the sun, sunlamps, and tanning beds.

Q: Does Unitrexate interact with hormonal birth control?

A: The medicine is a known teratogen and is contraindicated in pregnancy. Effective contraception must be used by both men and women of reproductive potential during and for a period after treatment to prevent pregnancy.

Q: Can Unitrexate cause skin rashes?

A: Yes, skin rash and skin irritation are listed as possible side effects in regulatory documents. It is important to note that rare but serious skin reactions, including blistering or peeling, have also been reported.

Q: Is it normal to feel extra tired when taking Unitrexate?

A: Yes, official adverse event profiles list general symptoms such as fatigue, dizziness, and a feeling of being unwell (malaise) as possible side effects.

Q: Can Unitrexate affect my mood or cause depression?

A: Official product information lists depression and mood swings as less common or rare psychiatric side effects that may occur in some patients.

Q: Why is Unitrexate prescribed for more than one condition?

A: This medicine is classified as an antineoplastic agent (used in cancer treatment) and an immunosuppressant (used to control immune activity). Its dual action allows it to be approved for treating certain types of cancer as well as severe autoimmune diseases such as rheumatoid arthritis and psoriasis.

Q: Why is folic acid often taken with Unitrexate?

A: Unitrexate works by blocking the body's use of folic acid (it is an anti-folate). Folic acid or folinic acid is frequently prescribed alongside it to help minimize the risk of developing certain side effects related to this action.

Q: Is Unitrexate a chemotherapy drug, or is that a misunderstanding?

A: The drug is officially classified as an antineoplastic agent and is used in high doses as a chemotherapy drug to treat certain cancers. In contrast, it is used in much lower doses to manage chronic autoimmune diseases.

Q: What are the signs of a serious side effect from Unitrexate?

A: Signs of serious side effects listed in regulatory warnings include unusual bruising or bleeding, fever, persistent dry cough, shortness of breath, severe diarrhea, mouth sores, or yellowing of the skin or eyes. Official labeling states these symptoms require immediate medical attention.

Q: What are the guidelines for discontinuing Unitrexate?

A: The product information states that treatment cessation or dose reduction must be performed under the supervision of a healthcare provider. Reasons for cessation listed in the product label often involve signs of serious toxicity to the liver, kidney, lungs, or bone marrow.

Q: Is Unitrexate a biologic drug?

A: No, this medicine is a synthetic organic compound. It is classified as an anti-folate antimetabolite. Biologic drugs, which are produced from living organisms, are a separate and distinct class of medication.

Q: How quickly does Unitrexate start to work after starting treatment?

A: Studies indicate that for chronic conditions like rheumatoid arthritis, it may take between 3 to 6 weeks to notice initial improvements. Further relief usually continues over the first three months of treatment.

Q: What happens if I miss a scheduled time to take Unitrexate?

A: Official patient information for the once-weekly schedule recommends consulting a healthcare provider for specific guidance. The labeling specifies that a double dose should not be taken to compensate for a forgotten dose, and directs skipping the dose if administration is too late.

Q: Is there a specific time of day that is best to take Unitrexate?

A: The key instruction is to take the medicine once per week on the same day. The tablets can generally be taken with or without food. Consultation with the prescribing physician is necessary for determining the specific time of day for administration.

Q: How long do most people stay on Unitrexate treatment?

A: Treatment for chronic autoimmune conditions like rheumatoid arthritis and psoriasis is often considered long-term. Clinical studies referenced in regulatory documents have demonstrated continuous use and effectiveness for periods exceeding ten years.

Q: Do clinical trials support the long-term use of Unitrexate?

A: Yes, official information references controlled clinical trials that have demonstrated use and effectiveness in patients with rheumatoid arthritis for up to 11 years of continuous therapy, which informs its use in long-term disease management.

Q: Does Unitrexate cause weight gain or weight loss?

A: Unexplained weight gain (especially with swelling) or unusual weight loss are mentioned in regulatory warnings as symptoms. These changes are listed as symptoms that require attention from a healthcare provider, as they may be signs of serious underlying problems, such as liver or kidney toxicity.

Q: Do I need to change my diet while taking Unitrexate?

A: Alcohol consumption is restricted due to the significant, additive risk of liver toxicity. Additionally, food or vitamin supplements containing folic acid or folate are substances to be avoided unless prescribed by a doctor.

Q: Can Unitrexate be taken with common vitamins or supplements?

A: Vitamin and mineral supplements containing folic acid or folate are listed as substances to be avoided unless prescribed. The product label indicates that other supplements should be reviewed with a healthcare provider for potential interactions.

Q: Is Unitrexate the same kind of drug as Plaquenil?

A: No. While both Unitrexate (Methotrexate) and Plaquenil (Hydroxychloroquine) are used to treat conditions like rheumatoid arthritis and are classified as Disease-Modifying Anti-Rheumatic Drugs (DMARDs), they belong to different therapeutic classes and work via different mechanisms.

Q: Can Unitrexate affect how my body heals from cuts or injuries?

A: The medication can cause a reduction in certain white blood cell counts (myelosuppression), which may increase the risk of infection. Any slow-healing injuries or signs of infection require evaluation by a healthcare provider.

Q: Is it okay to drink coffee or tea when using Unitrexate?

A: Regulatory advisories mention a study suggesting a potential for interaction in patients with rheumatoid arthritis who consume substantial amounts of caffeine (e.g., more than 180 mg per day), which could possibly lessen the drug's effect. Consultation with a healthcare provider regarding normal caffeine intake may be appropriate.

How should Unitrexate be stored and disposed of?

How to Store and Dispose of Unitrexate (Methotrexate Injection)

Official regulatory guidelines mandate specific storage and disposal requirements for Unitrexate, a classified hazardous drug, to maintain product integrity and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze or store above 30 C.
Protection Protect from light by keeping the product in its original carton.
Child Safety Must be kept in a safe place, out of the reach of children.

Stability and Disposal

Single-use vials must be discarded immediately after administration. Multiple-dose vials, if applicable, must be refrigerated (2 C to 8 C) after the first puncture and discarded after 30 days. All unused, expired, or used product, including associated supplies, must be disposed of according to special handling procedures for hazardous/cytotoxic waste, and not placed in household trash or down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unitrexate found in:

A-Z Index: